denotes an abstract that is clinically relevant.
denotes that this is a recommended PHD Trainee Session.
denotes that this is a ticketed session.Hematology Disease Topics & Pathways:
Biological, CRS, Diseases, Lymphoma (any), neurotoxicity, CAR-Ts, Therapies, Adverse Events, Biological Processes, gene therapy, Lymphoid Malignancies, immune mechanism, microenvironment
Description:
The anti-tumor immune response in lymphoma is typically compromised, exhausted or suppressed. Treatment strategies are being developed to manipulate the immune system and optimize immune function to generate a more effective anti-tumor immune response. In this session, we will discuss the fundamentals of immunotherapy for lymphoma, as well as strategies using checkpoint blockade, bispecific antibodies, novel drugs and cellular therapies to improve immune function.
Dr. Stephen Ansell will provide a general overview of the components that are necessary for an optimal anti-tumor immune response and highlight the immunological barriers to an adequate immune response that exist in patients with lymphoma.
Dr. Catherine Diefenbach will discuss the role of drugs in optimizing immune function in lymphoma. She will review clinical results with immune checkpoint blockade, bispecific antibodies, as well as small molecule inhibitors.
Dr. David Porter will review the use of cellular therapies in treating patients with lymphoma. He will discuss the biology, efficacy and side effects associated with cell-based approaches and the impact they are making on lymphoma management.
Dr. Stephen Ansell will provide a general overview of the components that are necessary for an optimal anti-tumor immune response and highlight the immunological barriers to an adequate immune response that exist in patients with lymphoma.
Dr. Catherine Diefenbach will discuss the role of drugs in optimizing immune function in lymphoma. She will review clinical results with immune checkpoint blockade, bispecific antibodies, as well as small molecule inhibitors.
Dr. David Porter will review the use of cellular therapies in treating patients with lymphoma. He will discuss the biology, efficacy and side effects associated with cell-based approaches and the impact they are making on lymphoma management.